Key result
Medical therapy fails to prevent fatal respiratory failure in breast cancer-associated pulmonary tumor thrombotic microangiopathy.
Why the study?
Early and definite diagnosis of pulmonary tumor thrombotic microangiopathy is currently challenging, and an optimal diagnostic and therapeutic strategy is warranted.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, rapidly progressive, and often fatal complication in patients with malignancy that requires early diagnosis and intensive therapy.
We report here a 70-year-old female patient with a history of breast cancer who presented with dyspnea that had lasted for 2 weeks following a long-distance trip by bus. She was at first suspected of having a pulmonary embolism given the typical presentation, elevated D-dimer level, and enlargement of the right-side heart. However, her systemic condition deteriorated despite the initiation of anti-coagulation therapy. Given the absence of a major thrombus in the pulmonary major arteries but multiple low perfusion lesions in the periphery of the lungs, refractoriness to conventional therapy, an increase in tumor markers, and anaplastic cells demonstrated by aspiration cytology from the pulmonary artery, we diagnosed her as pulmonary tumor thrombotic microangiopathy (PTTM). She died on day 23 due to respiratory failure despite administration of inotropes and prostaglandin I2. The patient had an obvious history of malignancy, but we should emphasize that PTTM can develop even in patients with early-stage or completely cured malignancies. Although an early and definite diagnosis of PTTM is currently challenging, an optimal diagnostic and therapeutic strategy is warranted.
No takes yet. Share an insight, caveat, or question.
Onoda et al. (2020) conducted a case report in Pulmonary tumor thrombotic microangiopathy (n=1). Inotropes and prostaglandin I2 was evaluated on Clinical outcome (survival). A 70-year-old female with a history of breast cancer diagnosed with pulmonary tumor thrombotic microangiopathy died on day 23 due to respiratory failure despite treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: